Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-ii symbols : INCY save search
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
Published: 2023-02-10 (Crawled : 19:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.3%
H: 0.1%
C: -2.15%
incb5470 results study phase 2
Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
Published: 2022-12-05 (Crawled : 12:20) - biospace.com/
SNDX | $20.82 1.61% 1.59% 850K
|
Health Technology
|
| O: -0.28%
H: 4.28%
C: 1.76%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.43%
H: 2.17%
C: 1.58%
pharmaceuticals disease phase 1
Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer
Published: 2022-03-01 (Crawled : 13:30) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.44%
H: 2.1%
C: 0.88%
phase 2 trial therapeutics therapy cancer pancreatic enroll
Incyte Withdraws Lymphoma Drug in "Business Decision"
Published: 2022-01-26 (Crawled : 16:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -1.27%
H: 2.58%
C: 0.42%
drug
Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
Published: 2021-06-04 (Crawled : 20:00) - biospace.com/
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: 0.38%
H: 1.25%
C: -0.76%
MOR | News | $17.96 -0.5% -0.5% 180K
|
Health Technology
|
| O: 3.74%
H: 3.11%
C: 2.76%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.33%
H: 1.54%
C: 0.19%
treatment phase 2 results als
Incyte Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
Published: 2021-04-23 (Crawled : 18:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.5%
H: 1.3%
C: 1.16%
phase 2
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.